In a significant move that underscores the evolving landscape of corporate finance in India, Blue Sapphire Healthcares Private Limited, the promoter of the renowned Asian Institute of Medical Sciences (AIMS), has successfully raised ₹415 crore in private credit from 360 ONE Asset Management. This strategic funding is primarily earmarked to facilitate the buyback of a 49% stake from its long-standing private equity investors, OrbiMed and British International Investment (BII), thereby consolidating full ownership under the Pandey family. A crucial portion of this capital has also been allocated to fuel the multi-specialty hospital chain’s ambitious growth plans, signalling a robust future for AIMS.
This transaction is more than just a financial deal; it represents a pivotal moment for AIMS, allowing its founders to reclaim complete strategic control and steer the institution towards its next phase of expansion with an unfragmented vision. It also highlights the increasing sophistication and utility of India’s private credit market, which is becoming a preferred route for promoters seeking flexible capital solutions to achieve strategic objectives without diluting future equity or succumbing to immediate exit pressures. For a healthcare provider of AIMS’s stature, operational continuity and a clear, long-term strategic roadmap are paramount, and this deal delivers precisely that.
About Asian Institute of Medical Sciences (AIMS)
Founded in 2010 by Dr. Narendra Pandey, a visionary in India’s healthcare sector, Blue Sapphire Healthcares Private Limited operates the Asian Institute of Medical Sciences (AIMS). Headquartered in Faridabad, within the bustling Delhi-NCR region, AIMS has, over the past decade and a half, meticulously built a reputation as a leading multi-specialty healthcare provider in North India. Dr. Pandey’s initial vision was to create a center of excellence, particularly in cardiac sciences, a field where he himself holds considerable expertise. From this strong foundation, AIMS has strategically expanded its service offerings to encompass a comprehensive array of tertiary and quaternary specialties.
Today, the AIMS platform boasts an aggregate capacity of approximately 1,000 beds across its four hospitals. The flagship facility in Faridabad, Haryana, is complemented by three other multi-specialty hospitals located in Dhanbad, Moradabad, and Patna. This geographical spread is a testament to the group’s strategy of not only serving the high-demand metropolitan areas but also addressing the critical need for quality healthcare infrastructure in Tier 2 and Tier 3 cities. Its comprehensive service portfolio now includes orthopaedics, oncology, nephrology, neurosciences, paediatrics, internal medicine, and a host of other critical care and surgical disciplines, making it a truly regional healthcare powerhouse.
The institution’s trajectory has been marked by consistent growth and a commitment to clinical excellence. In the financial year 2026, Blue Sapphire Healthcares reported an impressive revenue of approximately ₹560 crore, coupled with an EBITDA of ₹75-80 crore. These figures underscore the robust operational health and strong financial performance of the group, which has consistently focused on delivering high-quality, patient-centric care while maintaining a sustainable business model.
The Deal: Strategic Private Credit for Ownership Consolidation
The current funding round sees Blue Sapphire Healthcares securing ₹415 crore in private credit. This significant capital infusion was led by 360 ONE Asset Management, a prominent player in India’s alternative investment space, known for its expertise in providing bespoke financing solutions. The primary objective of this debt raise was to facilitate a secondary buyout, enabling the Pandey family to repurchase the 49% stake previously held by private equity investors OrbiMed and British International Investment (BII). While the specific valuation of the company was not publicly disclosed in conjunction with this transaction, the scale of the buyout reflects a substantial enterprise value and strong confidence in AIMS’s future prospects.
360 ONE Asset Management’s investment thesis in AIMS is deeply rooted in the hospital chain’s established market leadership and robust clinical franchise in North India. Mohit Khullar, Managing Director and Leader, Corporate Finance, at Alvarez & Marsal (A&M) India, who acted as exclusive financial advisor to the promoters, articulated the broader trend this deal exemplifies. He noted that such bespoke private credit solutions are increasingly being adopted by Indian promoter groups. This allows them to effectively address strategic shareholder objectives, such as consolidating ownership, while simultaneously preserving long-term control and operational continuity, elements often critical for family-led enterprises.
The decision by 360 ONE to back this promoter-led buyout signals its confidence not only in AIMS’s operational strength but also in the long-term vision of the Pandey family. It’s a clear endorsement of the hospital group’s proven track record and its potential for sustained growth in a critical sector. For OrbiMed and British International Investment, this secondary transaction provides a structured exit, allowing them to realize returns on their investment after a significant period of partnership, demonstrating the liquidity potential even in complex private equity holdings.
Deployment of Fresh Capital
The ₹415 crore raised through this private credit facility has a dual strategic purpose, meticulously planned to strengthen AIMS’s foundation and propel its future growth. The predominant portion of the funds is dedicated to the buyback of the 49% stake from exiting private equity investors, OrbiMed and British International Investment. This crucial step ensures that the Pandey family regains full ownership, thereby simplifying the cap table and granting them complete autonomy over the strategic direction and long-term vision of the Asian Institute of Medical Sciences.
Beyond this ownership consolidation, a smaller yet strategically vital portion of the funds has been earmarked for AIMS’s growth plans. While specific details of these growth initiatives are often kept proprietary, in the context of a multi-specialty hospital chain like AIMS, such capital is typically deployed across several key areas. This could include expanding bed capacity at existing facilities to meet surging patient demand, investing in cutting-edge medical technology and equipment to enhance diagnostic and treatment capabilities, or launching new super-specialty departments to broaden its clinical offerings. Furthermore, a portion may be allocated to talent acquisition, bringing in more specialist doctors and healthcare professionals, or to upgrading digital infrastructure to improve patient experience and operational efficiency. This judicious allocation ensures that the institution is not only financially robust but also well-equipped to innovate and expand its footprint and impact.
Market Opportunity: Tapping India’s Healthcare Imperative
The Indian healthcare sector presents an expansive and compelling market opportunity, driven by a confluence of factors including a burgeoning population, rising disposable incomes, increasing health awareness, and a growing incidence of lifestyle diseases. AIMS operates at the nexus of this opportunity, particularly within the multi-specialty hospital segment, which is experiencing significant demand for high-quality, comprehensive medical care. The Delhi-NCR region, where AIMS has its flagship presence, is one of the most densely populated and economically vibrant areas in India, with a constant need for advanced medical infrastructure.
Beyond the metros, AIMS’s strategic presence in Tier 2 and Tier 3 cities like Dhanbad, Moradabad, and Patna positions it uniquely to tap into underserved markets. These regions often lack the specialized medical facilities available in larger cities, leading to a significant patient outflow. By establishing robust multi-specialty hospitals in these areas, AIMS not only caters to local demand but also builds a loyal patient base, further strengthening its regional footprint. The growing penetration of health insurance and government initiatives aimed at improving healthcare access further bolsters the demand for organized healthcare providers.
While the Indian healthcare landscape is competitive, featuring large corporate chains like Apollo, Max, and Fortis, AIMS has carved out a distinct niche. Its strength lies in a combination of clinical excellence, a patient-centric approach, and a strategic focus on expanding specialized services. Its foundation in cardiac sciences, coupled with subsequent expansion into orthopaedics, oncology, nephrology, and neurosciences, reflects a shrewd understanding of evolving healthcare needs. The consolidation of ownership under the Pandey family, enabled by this private credit deal, grants AIMS the agility and long-term perspective required to navigate this dynamic market effectively, allowing for strategic decisions that prioritize patient care and sustainable growth over short-term financial pressures.
What’s Next for AIMS
With the successful consolidation of ownership and fresh capital for growth, Asian Institute of Medical Sciences is poised for a new chapter of expansion and innovation. Dr. Narendra Pandey, Chairman and Managing Director of AIMS, articulated this vision clearly, stating, “Partnering with 360 ONE Asset Management strengthens our ability to pursue our long-term growth ambitions while continuing to uphold the values and standards on which the institution was built.” This statement encapsulates the institution’s dual commitment: aggressive growth balanced with an unwavering dedication to its core values of quality care and ethical practice.
The immediate milestones for AIMS will likely revolve around solidifying its operational efficiencies and enhancing its service offerings. This could translate into further investment in advanced medical technologies, potentially expanding its robotic surgery programs, upgrading diagnostic imaging capabilities, or establishing new Centers of Excellence for specific disease areas. Geographical expansion, while not explicitly detailed, remains a strategic lever, whether through increasing bed capacity at existing high-performing facilities or exploring new locations where quality healthcare infrastructure is still nascent.
Furthermore, with full promoter control, AIMS can embark on longer-term strategic initiatives that might have been difficult with external private equity partners focused on specific exit timelines. This could include deeper investments in medical research, developing academic programs, or even exploring digital health solutions to extend its reach and improve patient engagement. The stability offered by the consolidated ownership positions AIMS to not only respond to the evolving needs of the Indian healthcare market but also to proactively shape its future, ensuring its continued legacy as a leading provider of multi-specialty medical care.
